The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical

mRNA vaccine for melanoma is hailed as a turning point in medicine

The data from Moderna and Merck’s trial have yet to be presented

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

For years, personalized cancer vaccines have promised to make a radical idea possible—a treatment designed not just for a particular type of cancer, but for the distinctive mutations in a patient’s tumor.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Intismeran autogene + Keytruda improves RFS and DMFS in melanoma patients, phase III INTerpath-001 trial finds

Intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy, plus Keytruda (pembrolizumab) improved recurrence-free survival and distant metastasis-free survival as an adjuvant treatment for patients with completely resected stage 2B-4 melanoma, according to results of the phase III INTerpath-001 trial. 
Podcast

What happened at FDA? Replimune approval raises questions

Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
Regulatory News

FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial

FDA has granted an accelerated approval to RP1 (vusolimogene oderparepvec) following the agency’s Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
By Jacquelyn Cobb and Paul Goldberg
Byline
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account